

CLAIMS

1. A recombinant nucleotide sequence ^{<i>} that encodes a protein sequence corresponding to a metallocarboxypeptidase inhibitor from *Hirudo medicinalis*.
- ~~2. A nucleotide sequence according to claim 1, characterized in that it comprises the sequence identified as SEQ ID N° 1 of the list of sequences.~~
- <2> 3. A polypeptide sequence encoded by the nucleotide sequence according to claims 1 and 2, characterized in that it comprises the sequence identified as SEQ ID N° 2 of the list of sequences.
- <3> 4. A polypeptide sequence according to claim ^{<2>} 3, wherein such sequence is substantially homologous to the sequence identified as SEQ N° 2.
- <4> 5. A nucleotide sequence that comprises a coding sequence of a polypeptide substantially homologous to the sequence ID N° 2, according to claim ^{<2>} 3.
- <5> 6. A prokaryotic or eukaryotic expression vector characterized in that it includes the recombinant nucleotide sequence of any of claims 1, ~~2~~ or ^{<4>} 5, and in that it is able to express the biologically active metallocarboxypeptidase inhibitor.
- <6> 7. A transformed *Escherichia coli* cell characterized in that it comprises an expression vector according to claim 6 and in that it is able to produce the biologically active metallocarboxypeptidase inhibitor.
- <7> 8. A procedure to prepare ^{<a>} the recombinant metallocarboxypeptidase inhibitor ^{<ii>} according to any of 30 claims ^{<2>} ^{<3>} 1 to 7 characterized in that it comprises

<i> = <identified as SEQ ID 1>

<ii> = <identified as SEQ ID 2>

(i) the culture of the transformant that contains an expression vector capable of expressing a biologically active metallocarboxypeptidase inhibitor; and

(ii) its obtention and purification.

- <8>5 ~~8~~. A procedure according to claim ~~8~~^{<7>} characterized in that the recombinant process takes place in a prokaryotic or eukaryotic host.
- <9> ~~10~~. A metallocarboxypeptidase inhibitor according to claims ~~2~~^{<2>} or ~~4~~^{<3>}, as fibrinolytic agent.
- <10> ~~10~~ ~~11~~. Use of the metallocarboxypeptidase inhibitor according to claims ~~3~~^{<2>} or ~~4~~^{<3>}, to prepare a drug useful as fibrinolytic agent.
- <11> ~~12~~. Use of the metallocarboxypeptidase inhibitor according to claim ~~11~~^{<10>}, in combination with other fibrinolytic agents 15 which it complements or enhances, to prepare a drug useful as fibrinolytic agent.
- <12> ~~13~~. A pharmaceutical composition that comprises, as active agent, an effective quantity of ~~<a>~~ the metallocarboxypeptidase inhibitor, ^{<iii>} or its derivatives, 20 ~~according to any of the previous claims,~~ and a pharmaceutically acceptable excipient.

<iii> = <identified as SEQ ID 2>